Latest Diagnostics News

Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.

Atomo Diagnostics has successfully closed a Share Purchase Plan and secured shareholder approval for a Tranche 2 Placement, raising a combined $1.53 million to support its ongoing operations.

Coventry Group Limited has appointed Nik Alpert as Acting Group CEO, while announcing the retirement of CFO Rod Jackson and the upcoming appointment of Patrick Maloney as his successor.

Coventry Group Limited has appointed Nik Alpert as Acting Group CEO and announced a planned CFO transition, signaling a new leadership phase for the industrial distributor.

Singular Health Group has completed a $7.85 million capital raising through a new share issue, alongside additional funds from option exercises, strengthening its financial position for growth in medical imaging technology.

Cleo Diagnostics has gained approval to access the prestigious PLCO biobank, a move set to strengthen its FDA submission and accelerate development of its ovarian cancer diagnostic tests.

BlinkLab Limited has responded to an ASX query regarding recent unusual trading activity, confirming no undisclosed material information exists and highlighting pending ADHD diagnostic results expected later this year.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.

Singular Health Group has inked a $1.3 million contract with Provider Network Solutions to deploy its 3DICOM imaging platform across key US states, backed by an $8 million capital raise to fuel national expansion.

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.